(Q34542908)

2 August 2017

1 reference

title

Preclinical and clinical results with the natural marine product ET-743 (English)

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1843

26 March 2024

main subject

marine natural product

0 references

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1843

26 March 2024

1

Maurizio D'Incalci

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585059

26 March 2024

author name string

José Jimeno

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

2 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/13543784.12.11.1843

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1843

Expert Opinion on Investigational Drugs

26 March 2024

published in

1 reference

2 August 2017

volume

12

1 reference

2 August 2017

issue

11

1 reference

2 August 2017

page(s)

1843-1853

1 reference

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

Telomere dysfunction increases cisplatin and ecteinascidin-743 sensitivity of melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1843

Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1843

26 March 2024

29

63

5902

DONALD S

2003

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1843

Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction

26 March 2024

30

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1843

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

26 March 2024

31

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1843

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

26 March 2024

49

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1843

26 March 2024

Identifiers

1 reference

2 August 2017

1 reference